Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P04626 (erbB-2)
 5,251 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Protein-tyrosine phosphatase (PTPase) activity in frozen human mammary primary carcinoma tissue sections has been quantitated using a modified histochemical assay. The improved method features the assay of PTPase activity in 12-microns sections of air-dried unfixed tissues, and the use of [2-(N-morpholino)-ethanesulfonic acid] (MES) buffer to prepare stable reaction solutions. Tissue samples from 53 primary human mammary carcinomas were assayed for PTPase activity, and immunohistochemically stained for c-erbB-2 protein-tyrosine kinase expression. Elevated levels of PTPase activity were found in 68% of the tumors compared with the level of activity found in normal human mammary tissues. PTPase activity was co-localized with pathology definitive for carcinoma. Excessive activity was demonstrated throughout the cell, with high activity evident in the cell cytoplasmic membrane and the nucleus. Coexistence of elevated expression of c-erbB-2 and increased PTPase activity was present in 53% of the tumors. In contrast, 15% displayed low c-erbB-2 expression and high PTPase activity, and 24% displayed high c-erbB-2 expression and low PTPase activity. No statistically significant association was found between increased PTPase activity and either c-erbB-2 overexpression or grade and stage of disease in primary human mammary tumors.
 ...
PMID:Histochemical staining of protein-tyrosine phosphatase activity in primary human mammary carcinoma: relationship with established prognostic indicators. 134 18

Malignant mesothelioma (MM) still remains a therapeutic and diagnostic problem to which new therapeutic perspectives are being continuously tried and tested. Three different primary cultures (MMGe-1, MES MM 98, and MES 1) and one immortalized cell line (MSTO 211 H) of human MM were studied in order to evaluate the HER-2/neu expression. Three out of four cell lines showed a different level of c-erbB-2 expression, the highest being detected on the MSTO 211 H cell line (fibroblastic phenotype), whereas MMGe-1 resulted negative. The effect of the anti-HER-2/neu antibody (Trastuzumab) alone, and in combination with cisplatin (CDDP) at different doses (ranging from 0.1 to 100 microg/ml), was studied on all the c-erB-2 positive cell lines. Trastuzumab was able to inhibit cell proliferation in a time-dependent manner, with growth inhibition also obtained at low concentrations (0.1-1 microg/ml). Combined treatment with Trastuzumab (10 microg/ml) and CDDP (1 microg/ml) showed synergism. Our results were encouraging, and suggest a rationale for further investigations in a clinical setting.
 ...
PMID:Synergistic effect of the anti-HER-2/neu antibody and cisplatin in immortalized and primary mesothelioma cell lines. 1220 78